摘要
交感神经系统是下泌尿生殖道生理功能的神经系统调节系统的组成部分。我们对这种同情系统的作用的认识S由于泌尿生殖系统中β3-肾上腺素受体(β3-Ars)的特性而在过去十年中取得了进展.本文主要从药理学和分子学方面对福的支持作用进行了综述。β3-AR在不同种属男性泌尿生殖组织中的作用。2010至2016年间,我们在两种不同的数据库中进行了电子搜索,其中包括:MEDLINE(PubMed)和EMBASE。β3-AGON基于现有证据,专家在治疗膀胱过度活动(OAB)方面可能是抗uscarinics的一种很有前途的选择。尽管最近的研究已经评估了β3-ars i的参与程度。在下泌尿生殖道各组织的生理调控方面,主要是膀胱、阴茎、尿道、输尿管等,在管道方面鲜有创新。在β3中-甲硝唑是一种独特的药物,用于治疗OAB患者。许多被归类为β3激动剂的药物仍在研究中,用于治疗下尿路OAB。症状,输尿管结石,良性前列腺增生,前列腺癌和勃起功能障碍。本文综述了β3-AR作为新的治疗靶点的潜在作用。与男性泌尿生殖道功能相关的临床前和临床研究。展望未来,对β3潜在的好处,从实验研究和临床AR激动剂ONS可能提供一个有吸引力的治疗方案。
关键词: β3-肾上腺素受体,药物作用,男性泌尿生殖系统,米来盖,排尿,膀胱过度活动.
图形摘要
Current Drug Targets
Title:β3-Adrenoceptor Control of Lower Genitourinary Tract Organs and Function in Male: An Overview
Volume: 19 Issue: 6
关键词: β3-肾上腺素受体,药物作用,男性泌尿生殖系统,米来盖,排尿,膀胱过度活动.
摘要: The sympathetic nervous system is one component of the nervous regulatory system of the physiological function of the lower genitourinary tract. Our knowledge on the role of this sympathetic system has advanced during the last decade due to the characterization of β3-adrenoceptors (β3-ARs) in the urogenital system. This review focuses on the pharmacological and molecular evidence supporting the functional roles of β3-AR in male genitourinary tissues of various species.
An electronic search in two different databases was performed including MEDLINE (PubMed) and EMBASE from 2010 to 2016. β3-agonists may be a promising alternative to antimuscarinics in the treatment of overactive bladder (OAB) based on available evidence.
Although more recent studies have evaluated the involvement of β3-ARs in the physiological control and regulation of various tissues of the lower genitourinary tract mainly urinary bladder, penis, urethra, ureter, there are few innovations in the pipe-line. Among the β3-agonists, mirabegron is a unique drug licensed for the treatment of patients with OAB. Many drugs classified as β3-agonists are still under investigations for the treatment of OAB, lower urinary tract symptoms, ureteral stones, benign prostate hyperplasia, prostate cancer and erectile dysfunction. This review discusses the potential roles of β3-AR as new therapeutic targets by evaluating the results of preclinical and clinical studies related to male lower genitourinary tract function. Looking into the future, the potential benefits of β3- AR agonists from experimental and clinical investigations may provide an attractive therapeutic option.
Export Options
About this article
Cite this article as:
β3-Adrenoceptor Control of Lower Genitourinary Tract Organs and Function in Male: An Overview, Current Drug Targets 2018; 19 (6) . https://dx.doi.org/10.2174/1389450118666170120165554
DOI https://dx.doi.org/10.2174/1389450118666170120165554 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ultrashort Echo Time Spectroscopic Imaging: Magnetic Resonance Assessment of Short-T2 Tissues in the Musculoskeletal System
Recent Patents on Medical Imaging Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma
Current Drug Discovery Technologies Advances in Development of Inhibitors of 17β-Hydroxysteroid Dehydrogenases
Anti-Cancer Agents in Medicinal Chemistry Prophylactic Potential of Conventional and Supercritical Garlic Extracts to Alleviate Diet Related Malfunctions
Recent Patents on Food, Nutrition & Agriculture Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets Fatty Acids - Induced Lipotoxicity and Inflammation
Current Drug Metabolism Calreticulin is Differentially Expressed in Invasive Ductal Carcinoma: A Comparative Study
Current Proteomics Influence of a Novel Inhibitor (UM8190) of Prolylcarboxypeptidase (PRCP) on Appetite and Thrombosis
Current Medicinal Chemistry Histone Variants and Composition in the Developing Brain: Should MeCP2 Care?
Current Topics in Medicinal Chemistry Applied Computational Techniques on Schizophrenia Using Genetic Mutations
Current Topics in Medicinal Chemistry Human Kallikreins: Common Structural Features, Sequence Analysis and Evolution
Current Genomics Recent Patents Relating to Tumor Suppressor Genes
Recent Patents on DNA & Gene Sequences The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
Current Medicinal Chemistry Cancer “Stemness”- Regulating MicroRNAs: Role, Mechanisms and Therapeutic Potential
Current Drug Targets Perspectives in Tissue Microarrays
Combinatorial Chemistry & High Throughput Screening Treating Benign Prostatic Hyperplasia with Botulinum Neurotoxin
Current Medicinal Chemistry Towards a “Metabolic” Subtype of Major Depressive Disorder: Shared Pathophysiological Mechanisms May Contribute to Cognitive Dysfunction
CNS & Neurological Disorders - Drug Targets Non Steroidal Anti Inflammatory Drugs As Gatekeepers Of Colon Carcinoma Highlight New Scenarios Beyond Cyclooxygenases Inhibition
Current Cancer Drug Targets Associations of Body Mass Index and Obesity-Related Genetic Variants with Serum Metabolites
Current Metabolomics Carvacrol Induced Program Cell Death and Cell Cycle Arrest in Androgen-Independent Human Prostate Cancer Cells via Inhibition of Notch Signaling
Anti-Cancer Agents in Medicinal Chemistry